Payment overview · 2025
General Payments
$552.80
21 reported records · 9 companies
Healthcare provider profile · identity verified
Nathan Pfeifer
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1750948188
Verified facts
What the public records show
CMS Open Payments records show Nathan Pfeifer received $552.80 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.68 | 28.9% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$151.43 | 27.4% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $72.59 | 13.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.80 | 8.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.11 | 7.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.60 | 6.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.12 | 3.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.28 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.19 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.80 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.37 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $136.87 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $116.56 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $78.26 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $73.17 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $72.59 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.33 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.33 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.33 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 661 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 91 |
| Lisinopril | Lisinopril | 372 | 89 |
| Losartan Potassium | Losartan Potassium | 349 | 80 |
| Gabapentin | Gabapentin | 322 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 71 |
| Potassium Chloride | Potassium Chloride | 252 | 54 |
| Metformin Hcl | Metformin Hcl | 233 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 55 |
| Furosemide | Furosemide | 222 | 44 |
| Omeprazole | Omeprazole | 203 | 51 |
| Simvastatin | Simvastatin | 202 | 51 |
| Meloxicam | Meloxicam | 179 | 52 |
| Trazodone Hcl | Trazodone Hcl | 176 | 30 |
| Sertraline Hcl | Sertraline Hcl | 167 | 37 |
| Tramadol Hcl | Tramadol Hcl | 157 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 40 |
| Warfarin Sodium | Warfarin Sodium | 135 | 17 |
| Eliquis | Apixaban | 130 | 22 |
| Allopurinol | Allopurinol | 122 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 27 |
| Famotidine | Famotidine | 111 | 22 |
| Prednisone | Prednisone | 110 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 32 |
| Alprazolam | Alprazolam | 108 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 15 |
| Methylprednisolone | Methylprednisolone | 103 | 83 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 81 |
| Carvedilol | Carvedilol | 96 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 47 |
| Donepezil Hcl | Donepezil Hcl | 87 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 87 | 17 |
| Ezetimibe | Ezetimibe | 83 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 14 |
| Farxiga | Dapagliflozin Propanediol | 79 | 14 |
| Alendronate Sodium | Alendronate Sodium | 72 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 27 |
| Metformin Hcl Er | Metformin Hcl | 71 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 25 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Baclofen | Baclofen | 64 | 25 |
| Azithromycin | Azithromycin | 63 | 54 |
| Lorazepam | Lorazepam | 62 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | suppressed |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Ozempic | Semaglutide | 56 | 11 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 15 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Memantine Hcl | Memantine Hcl | 47 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 38 |
| Pregabalin | Pregabalin | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 27 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Estradiol | Estradiol | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 20 |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 17 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.80 · 21 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INTELLIS ADAPTIVESTIM, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, PREVNAR 20, Prolastin-C Liquid, SYMPLICITY G3, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error